Intellia Therapeutics, Inc. (NTLA)

Intellia Therapeutics Stock Forecast

Stock Price Forecast

The 20 analysts that cover Intellia Therapeutics stock have a consensus rating of "Buy" and an average price target of $19.83, which forecasts a 106.35% increase in the stock price over the next year. The lowest target is $5.00 and the highest is $54.

Price Target: $19.83 (+106.35%)

Analyst Consensus: Buy

Target	Low	Average	Median	High
Price	$5.00	$19.83	$14	$54
Change	-47.97%	+106.35%	+45.68%	+461.91%

Analyst Ratings

The average analyst rating for Intellia Therapeutics stock is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.

Recommendation Trends

Rating	Jul '25	Aug '25	Sep '25	Oct '25	Nov '25	Dec '25
Strong Buy	7	8	6	7	7	7
Buy	7	6	6	5	4	4
Hold	6	6	7	8	10	10
Sell	0	0	0	0	1	1
Strong Sell	0	0	0	0	0	0
Total	20	20	19	20	22	22

Latest Forecasts

Analyst	Firm	Rating	Rating	Action	Price Target	Upside	Date
Andy Chen Wolfe Research	Wolfe Research	Buy → Hold Downgrades n/a	Buy → Hold	Downgrades	n/a	n/a	Nov 12, 2025
Debanjana Chatterjee Jones Trading	Jones Trading	Strong Buy → Hold Downgrades n/a	Strong Buy → Hold	Downgrades	n/a	n/a	Nov 11, 2025
Jonathan Miller Evercore ISI Group	Evercore ISI Group	Buy → Hold Downgrades $17 → $8	Buy → Hold	Downgrades	$17 → $8	-16.75%	Nov 11, 2025
Joon Lee Truist Securities	Truist Securities	Strong Buy Reiterates $25 → $14	Strong Buy	Reiterates	$25 → $14	+45.68%	Nov 10, 2025
Mitchell S. Kapoor HC Wainwright & Co.	HC Wainwright & Co.	Strong Buy Maintains $18 → $15	Strong Buy	Maintains	$18 → $15	+56.09%	Nov 10, 2025

More Analyst Ratings

Financial Forecast

Revenue This Year

59.01M

Increased by 1.96%

from 57.88M

Revenue Next Year

54.84M

Decreased by -7.06%

from 59.01M

EPS This Year

-4.04

from -5.25

EPS Next Year

-3.70

from -4.04

Fiscal Year	FY 2020	FY 2021	FY 2022	FY 2023	FY 2024	FY 2025	FY 2026
Period Ending	Dec 31, 2020	Dec 31, 2021	Dec 31, 2022	Dec 31, 2023	Dec 31, 2024	Dec 31, 2025	Dec 31, 2026
Revenue	57.99M	33.05M	52.12M	36.28M	57.88M	59.01M	54.84M
Revenue Growth	34.55%	-43.01%	57.69%	-30.40%	59.55%	1.96%	-7.06%
EPS	-2.40	-3.78	-6.16	-5.42	-5.25	-4.04	-3.70
EPS Growth	-	-	-	-	-	-	-
Forward PE	-	-	-	-	-	-	-
No. Analysts	-	-	-	-	-	26	25

Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.

Revenue Forecast

Revenue	2025	2026	2027	2028	2029	2030
High	71.7M	105.0M
Avg	59.0M	54.8M
Low	51.4M	8.8M

Revenue Growth

Revenue Growth	2025	2026	2027	2028	2029	2030
High	23.9%	77.9%
Avg	2.0%	-7.1%
Low	-11.2%	-85.1%

EPS Forecast

EPS	2025	2026	2027	2028	2029	2030
High	-3.99	-2.06
Avg	-4.04	-3.70
Low	-4.03	-4.47

EPS Growth

EPS Growth	2025	2026	2027	2028	2029	2030
High	-	-
Avg	-	-
Low	-	-

Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.